(Q47271726)

13 January 2018

title

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease (English)

1 reference

13 January 2018

1 reference

1 reference

9

Paul Rutgeerts

1 reference

13 January 2018

1

Stephen B Hanauer

1 reference

13 January 2018

author name string

Carrie L Wagner

2

1 reference

13 January 2018

Mohan Bala

3

1 reference

13 January 2018

Lloyd Mayer

4

1 reference

13 January 2018

Suzanne Travers

5

1 reference

13 January 2018

Robert H Diamond

6

1 reference

13 January 2018

Allan Olson

7

1 reference

13 January 2018

Warren Bao

8

1 reference

13 January 2018

language of work or name

English

0 references

publication date

1 July 2004

1 reference

13 January 2018

Clinical Gastroenterology and Hepatology

published in

1 reference

13 January 2018

volume

2

1 reference

13 January 2018

page(s)

542-553

1 reference

13 January 2018

issue

7

1 reference

13 January 2018

Therapeutic antibodies: magic bullets hit the target.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900238-1

7 January 2021

Immunogenicity of recombinant DNA human insulin

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900238-1

7 January 2021

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900238-1

7 January 2021

Mouse/human chimeric monoclonal antibody in man: kinetics and immune response

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900238-1

7 January 2021

The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900238-1

7 January 2021

Tumour necrosis factor alpha in stool as a marker of intestinal inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900238-1

7 January 2021

Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900238-1

7 January 2021

Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900238-1

7 January 2021

Tumour necrosis factor α and interleukin 1β in relapse of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900238-1

7 January 2021

Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900238-1

7 January 2021

Role of cytokines in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900238-1

7 January 2021

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900238-1

7 January 2021

Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900238-1

7 January 2021

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900238-1

7 January 2021

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900238-1

7 January 2021

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900238-1

7 January 2021

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900238-1

7 January 2021

10.1016/S1542-3565(04)00238-1

Identifiers

DOI

1 reference

13 January 2018

PubMed ID

15224278

1 reference

13 January 2018